12月12日 - ** 医疗保健科技公司Veeva Systems VEEV.N股价盘前下跌约3%，报223.74美元
** KeyBanc将该公司股票评级从 "超配 "下调至 "行业减持"。
** 券商称，正处于软件评估阶段的大型制药客户倾向于SalesforceCRM.N的产品，这表明损失比VEEV概述的更多。
** 还称已有大量中小型企业客户从 VEEV 迁移到 CRM。
** 34家券商中有22家将该股评级为 "买入 "或更高，10家为 "持有"，2家券商将该股评级为 "卖出 "或更高；PT中值为320美元--数据由LSEG编制
** 截至上次收盘，该股今年累计上涨 9
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.